ADTpared with RT plus months of ADT 8 TROG : decreased distant progressi prostate cancer-specific mortality and all-cause mortality with months of ADT prior to and during definitive RT vs. RT alone 6 Biochemically recurrent prostate cancer Biochemical  asenapine progression Optimal timing of ADT is controversial. Factors that may prompt early initiation of ADT include a PSA level of approximately 0 ng ml , an interval between primary treatment and PSA failure of f years or PSA doubling time f months. Metastatic prostate cancer Metastatic disease Bilateral orchiectomy or medical castration with a GnRH agonist rmended as initial therapy. CAB may also be considered as initial therapy Associated with improvements in quality of life but no clear survival benefit to date.

Second-line androgen-suppressive strategies include GnRH antagonists and adrenal CY 7 inhibitors Improved PFS and reduced incidence of metastatic disease with 4 months of  TG-101348 daily bicalutamide during and after RT in patients following radical prostatectomy with pathological disease and elevated PSA levels 6 Borderline OS advantage in favor of CAB over GnRH agonist monotherapy with no difference in cause-specific survival between arms 2 No OS difference with use of an intermittent ADT vs. continuous strategy in men with locally advanced or metastatic prostate cancer whose PSA decreased t ng ml or had a . 0 decrease in PSA after months of ADT induction 0 No OS difference with the use of an intermittent ADT vs. continuous strategy in men with biochemical progression . year after initial or salvage RT. Possibly longer time to  Voriconazole 137234-62-9 development of castration resistance on the IAD a although this may be artifact Improved PSA response and reduced PSA progression at months in men receiving first-line ADT plus docetaxel。

ADT alone 0 Degarelix non-inferior to leuprolide at maintaining low testosterone levels over a-year period and induced testosterone and PSA suppression significantly faster than leuprolide 3 Greater PSA declines o 0 and objective tumor responses with ketoconazole vs. androgen withdraw but no survival benefit 8 Improved OS with the use of abiraterone  buy Vincristine acetate vs. placebo in men with chemotherapy-pretreated castration-resistant prostate cancer 7 Abbreviations: A androgen deprivation therapy; C bined androgen blockade; NC the nationalprehensive cancer network; overall survival; P progression-free survival; P prostate-specific antigen; radiation therapy. or biochemical failure rat or indeed in survival. There was a sug-gestion of benefit for patients with high-risk disease who accounted for 7 of the study population. 1 In summa based on the available data and our collective clinical experien the authors generally advocate the use of months of Asian Journal of Andrology ADT for men with intermediate-risk localized prostate cancer undergoing definitive external beam but not for men with low-risk localized prostate cancer.

In the latter populati ADT not only does not improve sur-viv but it may even be harmf and this practice should be avoided. ADT in prostate cancer RM Connolly High-risk and locally advanced prostate cancer. A number of large randomized trials have demonstrated a  flagella survival advantage with the addition of a GnRH agonist to radiation in men with locally advanced prostate.